Chinese prosecutors have brought formal charges against AstraZeneca and its former executives following investigations into ...
J&J kicked off the new year with a bang, shelling out more than $78 million to air eight TV ads for Tremfya throughout ...
But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- ...
Gilead Sciences is coming off of a milestone year that saw the start of the much-anticipated launch of the world’s first twice-yearly injectable HIV pre-exposure prophylaxis (PrEP) medicine Ye | ...
As the U.S. backpedals on its mRNA investment, Mexico is embracing the technology through a new manufacturing pact with ...
After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030 ...
With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the ...
Breast cancer drug Kisqali outperformed its 2025 sales target by 9%, while a portfolio of recent launches that includes radioligand therapy Pluvicto, kidney disease drugs Fabhalta and Vanrafia, and ...
A batch of untitled letters posted on the FDA’s database in recent days takes aim at what the agency has termed “false or misleading” drug ads from the likes of Novo Nordisk, argenx and Sobi. | A ...
PharmaEssentia will spend $46 million to build a new manufacturing facility in Puerto Rico. The move forms part of the ...
Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of Novo Nordisk's new ...
After a brief delay last month, another piece of the Trump administration’s healthcare policy has fallen into place. | ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results